Carl Zeiss Meditec Valuation
Is AFXD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AFXD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AFXD (€57.98) is trading below our estimate of fair value (€58.92)
Significantly Below Fair Value: AFXD is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AFXD?
Key metric: As AFXD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is AFXD's PE Ratio? | |
|---|---|
| PE Ratio | 25.7x |
| Earnings | €203.20m |
| Market Cap | €5.23b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 18.3x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does AFXD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.9x | ||
SN. Smith & Nephew | 34.7x | 22.5% | UK£8.4b |
NIOX NIOX Group | 23x | 17.1% | UK£253.1m |
CTEC ConvaTec Group | 41.9x | 20.6% | UK£5.1b |
EKF EKF Diagnostics Holdings | 23.8x | n/a | UK£113.4m |
AFXD Carl Zeiss Meditec | 25.7x | 16.3% | €5.2b |
Price-To-Earnings vs Peers: AFXD is good value based on its Price-To-Earnings Ratio (25.7x) compared to the peer average (30.9x).
Price to Earnings Ratio vs Industry
How does AFXD's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: AFXD is good value based on its Price-To-Earnings Ratio (25.7x) compared to the European Medical Equipment industry average (29.7x).
Price to Earnings Ratio vs Fair Ratio
What is AFXD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 25.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AFXD's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €67.80 0% | 12.9% | €90.00 | €54.00 | n/a | 15 |
| Nov ’25 | €57.25 | €68.80 +20.2% | 14.1% | €90.00 | €54.00 | n/a | 15 |
| Oct ’25 | €67.15 | €70.00 +4.2% | 13.5% | €90.00 | €54.00 | n/a | 15 |
| Sep ’25 | €66.23 | €71.13 +7.4% | 12.1% | €90.00 | €56.00 | n/a | 15 |
| Aug ’25 | n/a | €75.07 0% | 14.9% | €105.00 | €56.00 | n/a | 15 |
| Jul ’25 | n/a | €82.00 0% | 24.9% | €140.00 | €56.00 | n/a | 15 |
| Jun ’25 | n/a | €103.87 0% | 19.6% | €145.00 | €68.00 | n/a | 15 |
| May ’25 | n/a | €108.67 0% | 18.4% | €150.00 | €70.00 | n/a | 15 |
| Apr ’25 | n/a | €105.47 0% | 21.8% | €150.00 | €59.00 | n/a | 15 |
| Mar ’25 | €111.10 | €101.93 -8.3% | 19.7% | €140.00 | €59.00 | n/a | 14 |
| Feb ’25 | n/a | €97.57 0% | 21.4% | €140.00 | €52.00 | n/a | 14 |
| Jan ’25 | n/a | €96.62 0% | 20.6% | €140.00 | €52.00 | n/a | 13 |
| Dec ’24 | €83.70 | €103.08 +23.2% | 16.9% | €140.00 | €74.00 | n/a | 12 |
| Nov ’24 | €80.61 | €105.73 +31.2% | 14.9% | €140.00 | €87.00 | €57.25 | 11 |
| Oct ’24 | €80.10 | €113.36 +41.5% | 19.3% | €175.00 | €87.00 | €67.15 | 11 |
| Sep ’24 | €92.28 | €114.36 +23.9% | 19.6% | €175.00 | €87.00 | €66.23 | 11 |
| Aug ’24 | €105.63 | €127.36 +20.6% | 17.9% | €175.00 | €90.00 | n/a | 11 |
| Jul ’24 | €98.96 | €130.64 +32.0% | 16.8% | €175.00 | €90.00 | n/a | 11 |
| Jun ’24 | €107.75 | €130.64 +21.2% | 16.8% | €175.00 | €90.00 | n/a | 11 |
| May ’24 | n/a | €134.27 0% | 18.7% | €175.00 | €90.00 | n/a | 11 |
| Apr ’24 | €125.55 | €140.27 +11.7% | 22.9% | €195.00 | €76.00 | n/a | 11 |
| Mar ’24 | €128.75 | €140.27 +8.9% | 22.9% | €195.00 | €76.00 | €111.10 | 11 |
| Feb ’24 | €132.15 | €136.27 +3.1% | 24.7% | €195.00 | €69.00 | n/a | 11 |
| Jan ’24 | n/a | €136.90 0% | 25.8% | €195.00 | €69.00 | n/a | 10 |
| Dec ’23 | €130.05 | €139.55 +7.3% | 24.9% | €195.00 | €69.00 | €83.70 | 11 |
| Nov ’23 | €119.20 | €141.00 +18.3% | 25.3% | €195.00 | €69.00 | €80.61 | 11 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Arjo
SEK 9.3b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 34.29
7D
-3.8%
1Y
-8.6%
Elevance Health
US$92.9b
Operates as a health benefits company in the United States.
0HG8
US$401.96
7D
-5.7%
1Y
-13.6%
Centene
US$29.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$57.48
7D
-6.3%
1Y
-20.9%